GoldenGolden
AVM Biotechnology

AVM Biotechnology

AVM Biotechnology is a biotechnology company developing regenerative medicines.

AVM Biotechnology is a biotechnology company that is developing and advancing AVM0703, a patent-pending exclusive formulation. Its AVM0703 triggers the production and release of highly active and powerful novel immune cells.

AVM Biotechnology has the mission to develop and deliver treatments that save lives and improve outcomes by unlocking the untapped potential of the body’s own immune system.

AVM Biotechnology was launched by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 47 patents, Dr. Deisher leads a team of scientists who are dedicated to changing what a diagnosis of cancer, autoimmunity, or chronic infectious disease means to patients and their loved ones. The company received FDA IND approval to test its lead product AVM0703 for the treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has received permission to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS.

Timeline

2008
AVM Biotechnology was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

AVM Biotechnology raising $17.5M to improve safety and delivery of stem cells

Web

Biotech Firm To Provide Ethical Alternatives For All Aborted Fetal Vaccines

Children of God for life

Web

This biotech company may be on the verge of a boom - but they only want pro-life investors

Steve Weatherbe

Web

Documentaries, videos and podcasts

Title
Date
Link

AVM Biotechnology - How Stem Cells Work and the Science of the Spleen

June 6, 2017

AVM Biotechnology Presents at Biotech & Money in London, UK

February 13, 2018

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
AVM Biotechnology, LLC
January 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Dr. Manon Cox will assume the role of CEO and Dr. Gary Grohmann the role of Chief Regulatory Officer, while retaining their positions on the...
AVM Biotechnology, LLC
December 2, 2020
www.prnewswire.com:443
/PRNewswire/ -- AVM Biotechnology, a company developing a proprietary and innovative form of dexamethasone, today announced that CEO/CSO, Dr. Theresa Deisher...
BioSpace
June 10, 2020
BioSpace
AVM Biotechnology announced today that Dr. Manon Cox and Dr. Gary Grohmann, both international experts on respiratory viruses and vaccine development, have joined AVM Biotechnology's Board of Directors.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.